Crohn's disease: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• TNF 7
• IL-23 10
• JAK 0
• NLRP3 0
• IL-1 0
• GLP-1 0
• LRRK2 0
• IL-17 0
• IL-6 0
• MAPK 0
• PPAR 0
• CD19 3
• JNK 0
• STAT3 0
• TLR4 0
• TP53 0
• AKT 0
• AMPK 0
• BCMA 2
• CCR5 0
• IL-4 0
• NRF2 0
• SIRT1 0
• STING 0
• YAP 0
• ACE2 0
• AXL 0
• BRD4 0
• CD30 0
• CD40 0
• CD47 0
• COX-2 0
• CTLA-4 0
• DPP-4 0
• FTO 0
• G6PD 0
• GIP 0
• GPX4 0
• HDAC 1
• HIF-1 0
• HMGB1 0
• IL-13 0
• IL-15 1
• KMT2A 0
• MMP-9 0
• mTOR 0
• MUC1 0
• PARP 0
• PD-1 0
• PD-L1 0
• PDE4 0
• PI3K 0
• PINK1 0
• RAS 0
• RUNX1 0
• TFEB 0
• TYK2 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-RIA

  Secretome bAsed Therapy for complex perianal fistUlas in CRohN’s disease (SATURN)

  Everzom· Paris, France· EU contribution €13,286,449· until Sept 2031· 5 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Characterising the molecular and cellular basis of enteric nervous system alterations in the inflamed gut (NeurogENSity)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €206,888· until Aug 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  A Fibroblast-Targeting Advanced Lead Mitigating Inflammation and Fibrosis in IBD (FIBROLEAD)

  Inolysis Monoprosopi Idiotiki Kefalaiouchiki Etaireia· Melissia Athens, Greece· EU contribution €150,000· until Jan 2027

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  RNA Epithelial Approach for Crohn’s Treatment (RE-ACT)

  Medical Research Infrastructure Development and Health Services Fund By the Sheba Medical Center· Ramat Gan, Israel· EU contribution €150,000· until Nov 2026

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Unravelling neuroimmune crosstalk to find novel treatment targets for inflammatory bowel disease (UNTANGLED)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €432,468· until Apr 2028· 2 countries

5 of 17 running projects, newest first. Listed amounts together: €63.7m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 22
• Organoids 13
• Mendelian Randomization Analysis 44
• Gene Expression Profiling 48
• Sequence Analysis, RNA 6
• Exome Sequencing 4
• Proteomics 14
• Metabolomics 23
• Mass Spectrometry 5
• Flow Cytometry 6
• Immunohistochemistry 9
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 76
• Machine Learning 36
• Deep Learning 13
• Cohort Studies 97
• Genome-Wide Association Study 58

• Metabolomics predict treatment response to vedolizumab in pediatric IBD: results from the prospective VedoKids cohort study.

  Inflamm Bowel Dis, Oct 2026

• A robustness-first cross-disease framework supports a candidate shared microbial redox axis and disease-specific metabolic divergence in colorectal cancer, Crohn's disease, and liver cirrhosis.

  mSystems, Sept 2026

• Blood Bile Acids for Inflammatory Bowel Disease Diagnosis and Disease Activity Assessment: A Metabolomics Meta-Analysis.

  J Proteome Res, Sept 2026

• Metabolome remodeling with reverse-engineered exclusive enteral nutrition in children with active Crohn's disease.

  Inflamm Bowel Dis, Sept 2026

• Multi-omics-based machine learning model predicts response and guides treatment in Crohn disease: a case study in nutritional therapy.

  Inflamm Bowel Dis, Aug 2026

• Urinary Organic Acid Profiling by GC-MS Reveals Distinct Metabolic Signatures for Non-Invasive Diagnosis and Disease Activity Monitoring of Inflammatory Bowel Disease.

  Int J Mol Sci, Jul 2026

• Role of Fatty Acid Oxidation in Crohn's Disease and Ulcerative Colitis: Metabolomics Analysis and Experimental Evidence.

  Cell Biochem Funct, Jul 2026

• Multiomics analysis dissects the molecular foundation of perianal fistulas associated with Crohn's disease and of cryptoglandular origin.

  J Crohns Colitis, Jun 2026

• Potential of Clinical Care-Collected Gut Biopsies for Advancing Personalised Medicine in Inflammatory Bowel Disease.

  United European Gastroenterol J, Jun 2026

• Lonely minds, inflamed guts: metabolic and circulating protein pathways linking social isolation and loneliness to inflammatory bowel disease.

  Transl Psychiatry, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.